Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001
Public ClinicalTrials.gov record NCT02868229. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Randomized, Double-blind, Placebo Controlled, Cohort Dose-escalation Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of multiple doses of COR-001 or placebo
Study identification
- NCT ID
- NCT02868229
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 61 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 12, 2016 (Actual)
- Primary completion
- Dec 11, 2018 (Actual)
- Completion
- Dec 11, 2018 (Actual)
- Last update posted
- Jul 30, 2021
2016 – 2018
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Northridge | California | 91324 | — |
| Novo Nordisk Investigational Site | Hollywood | Florida | 33025 | — |
| Novo Nordisk Investigational Site | Tampa | Florida | 33614 | — |
| Novo Nordisk Investigational Site | Augusta | Georgia | 30909 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60643 | — |
| Novo Nordisk Investigational Site | North Brunswick | New Jersey | 08902 | — |
| Novo Nordisk Investigational Site | Astoria | New York | 11102 | — |
| Novo Nordisk Investigational Site | Fresh Meadows | New York | 11365 | — |
| Novo Nordisk Investigational Site | Great Neck | New York | 11021 | — |
| Novo Nordisk Investigational Site | Providence | Rhode Island | 02915 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77099 | — |
| Novo Nordisk Investigational Site | San Antonio | Texas | 78215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02868229, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2021 · Synced Oct 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02868229 live on ClinicalTrials.gov.